-
- Sign In
- Tests
-
Invitae testsFollow-up testingFrequently ordered panels
- How to order
-
Getting startedEssentialsSponsored programs
- Resources
-
Clinical resourcesEducational materialsWorking together
- Technology
-
Our technologyA new gold standardData sharing
- FAQ
- FOR PATIENTS
- CONTACT
- FAQs / SUPPORT
Genetic testing for hereditary breast cancer
Rapid genetic testing to inform surgical decisions
Start an order
85% of breast cancer patients who met clinical guidelines for genetic testing never received it—an estimated 800,000 women in the US.1
Patients who do not meet clinical guidelines for genetic testing have positive rates nearly as high as patients who meet guidelines.2
Benefits of testing
Genetic information impacts surgical decisions and future diagnoses
Test options
Up-to-date clinical guideline criteria to help identify patients at risk
Results
Understanding your patients’ results and next steps
Invitae advantage
Fast, affordable, high-quality genetic testing you can count on
Benefits of genetic testing
Genetic testing can uncover actionable findings, leading to a significant change in clinical management.
Cancer treatment
Rapid or STAT genetic test results can inform quick surgical decisions without disrupting treatment timelines. Genetic information may qualify patients for participation in clinical trials or research studies.
Future diagnoses
Increased surveillance can identify cancer at its earliest, most treatable stage. Risk-reducing surgery and/or chemoprevention can significantly decrease the chance of future cancers in the same or different organ systems.
Family members
Genetic information can benefit close relatives and allow for risk stratification. Relatives at high risk can undergo enhanced surveillance, while those without the family variant may be able to avoid unnecessary procedures.
Typical testing criteria for insurance coverage
If your patient—or one of their close blood relatives—has any of the following, most insurance providers will cover genetic testing:*
- Early-onset breast cancer (age 45 or younger)
- Triple-negative breast cancer at or before age 60
- Male breast cancer
- Multiple BRCA-associated cancers in the same person
- A family history of ovarian, breast, pancreatic, melanoma, or prostate cancer
- Breast or ovarian cancer and Ashkenazi Jewish ancestry
- Ovarian cancer
Although the great majority of patients who select insurance billing already pay less than $100 out of pocket with Invitae, our simple out-of-pocket cost estimator can bring peace of mind.
For patients who do not meet their insurance company's testing criteria, we offer $250 patient-pay pricing.
Invitae Breast Cancer STAT Panel
A panel curated for breast surgeons with rapid results in 7 days on average
Invitae Common Hereditary Cancers Panel
A comprehensive cancer panel with results in 14 days on average
Not sure which panel is right for your patient?
Consult with one of our board-certified genetic counselors, available Monday through Friday, 5 am to 5 pm Pacific, to identify patients who could benefit from testing and differentiate between tests.
Ready to get started? Create an account today.
Create an accountWhat to do with your patients' results
|
|
Positive result Refer to our clinical medical management guide for actionable, gene-specific next steps. Download the guide > Test blood relatives at no additional charge with Invitae’s family variant testing program. Learn more > |
|
|
Negative result Expand to a larger hereditary cancer panel (if appropriate) within 90 days of receiving results, at no additional charge. View all cancer panels > Our board-certified genetic counselors are available to answer your questions about test results and even counsel your patients directly. Clinical consult > |
STAT panels for time-sensitive breast cancer cases offer rapid results in 5–12 calendar days (7 days on average). Expand to a larger panel at no additional charge within 90 days.
Invitae testing is covered by most insurance plans, and we will not hold a sample or report while managing insurance claims.
Invitae offers a $250 patient-pay option and a patient assistance program.
Genetic counselors are available on demand to help identify patients who could benefit from testing, discuss tough cases, and even counsel your patients directly.
Get started
|
|
1. Request free kits for collecting patient specimens
|
|
|
2. Order a test using Invitae’s HIPAA-compliant online portal or on paper
|
|
|
3. Receive an email when your results are ready (14 days on average)
|
Take the first step by requesting a free specimen collection kit or starting an order today.
Tools for your clinic
Invitae’s reference guides offer direction on when to consider genetic testing and provide management guidelines. We have also created patient resources for you to share with your patients when speaking to them about genetic testing, like the video below.
CancerCHECK
Identify patients who meet typical criteria for insurance coverage
Family history questionnaire
Collect your patient’s full family history to inform management
Management guidelines
Clinically actionable management guidelines for positive results, gene by gene
Risks and references poster
Gene by gene risks for cancer, categorized by organ system
Have a question or comment? Let us know.
Our team is here to answer your questions about ordering, billing, policies, and logistics as you are becoming familiar with our services.
Subscribe to our mailing list
Stay updated on the latest in hereditary breast cancer. We will send you information on relevant topics once or twice a month.
*These criteria have been adapted from current professional society guidelines. This is not an exhaustive list. Insurance criteria differ across providers. Patients who fit these criteria are not guaranteed to be covered by insurance for genetic testing.
References:
1. Childers CP et al. National estimates of genetic testing in women with a history of breast or ovarian cancer. J Clin Oncol. 2017;35(34):3800-6.
2. Beitsch P et al. Are genetic testing guidelines still relevant? Presented at: the American Society of Breast Surgeons Annual Meeting; May, 2018: Orlando, FL.
3. Yadav S et al. Outcomes of retesting BRCA negative patients using multigene panels. Fam Cancer. 2017;16(3):319-28.
4. Lincoln SE et al. A systematic comparison of traditional and multigene panel testing for hereditary breast and ovarian cancer genes in more than 1000 patients. J Mol Diagn. 2015;17(5):533-44.
